Stocktoria
Camp4 Therapeutics Corp CAMP
Camp4 Therapeutics Corp (CAMP) earns a Piotroski F-score of 3/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $3.5M at a -2298.5% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 3/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.837 |
| Retained earnings / assets | -2.48 |
| EBIT / assets | -0.446 |
| Equity / liabilities | 0.68 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CAMP | Camp4 Therapeutics Corp | 3/9 | -4.88 | — | — |
| MRKR | Marker Therapeutics, Inc. | 2/9 | — | — | — |
| TXMD | TherapeuticsMD, Inc. | 5/9 | — | — | — |
| CRVO | CervoMed Inc. | 1/9 | -12.9 | — | — |
| XBIO | Xenetic Biosciences, Inc. | 3/9 | — | — | — |
| ATAI | AtaiBeckley Inc. | 4/9 | — | — | — |
| UPB | Upstream Bio, Inc. | 2/9 | — | — | — |
About Camp4 Therapeutics Corp
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
FAQ
Is CAMP financially healthy?
Camp4 Therapeutics Corp's Piotroski F-score is 3/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does CAMP pay a dividend?
No, Camp4 Therapeutics Corp does not currently pay a dividend.
How profitable is CAMP?
In FY2025, Camp4 Therapeutics Corp had a net margin of -2298.5% and a return on equity of -168.5%.
What is the analyst price target for CAMP?
The average Wall-Street price target for Camp4 Therapeutics Corp is $8.58, about 89.5% above the recent price, from 6 analysts (consensus: strong buy).
Is CAMP a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Camp4 Therapeutics Corp: a Piotroski F-score of 3/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.